The UK cardiovascular clinical trials market size was estimated at USD 507.8 million in 2025 and is projected to reach USD 892.2 million by 2033, growing at a CAGR of 7.6% from 2026 to 2033. he market growth is driven by integrated healthcare data access, strong research funding, and regulatory acceleration.
In the country, the integrated infrastructure of the National Health Service (NHS) enables access to ~67 million patient records, which is expected to drive the recruitment and real-world evidence generation for cardiovascular clinical trials. In addition, the growing prevalence of cardiovascular disease (~7.6 million patients) has driven an increase in clinical trials, further contributing to market growth.
The UK cardiovascular clinical trials industry is growing due to rising cardiovascular disease burden in the country, regulatory acceleration and adaptive trial frameworks in the UK, and increasing investment in cardiovascular drugs innovation and late-stage pipelines. Due to the rising incidence of cardiovascular disease across the UK, there is continued demand for long-term, large-scale clinical trials. Cardiovascular conditions like heart failure, coronary heart disease (CHD), atrial fibrillation, and ischemic heart disease require ongoing innovations in medications and treatment. This is mainly responsible for the growing number of clinical trials in the country, as these trials are usually conducted using evidence from real-world experiences from NHS databases.
The data published by the British Heart Foundation (BHF) in January 2026 stated that nearly 7 million people currently live with cardiovascular disease in England. The growing and aging population is further expected to boost the rate of CVDs, owing to improved survival rates from cardiovascular events. As the risk of CVD increases with age, by 2030, the population in England aged 65-84 is anticipated to increase by 29% and those aged over 85 by 61%. Furthermore, CVDs are also responsible for ~26% (140,000) of the total deaths in the country per year, which equates to 380 people per day. Amongst which, 38,000 people die under the age of 75 in England each year. Such a growing burden of CVDs in the country has increased the demand for new interventions and treatments, as the government and the public health authorities-led efforts aimed at reducing deaths from cardiovascular disease are providing a steady stream of financial support to clinical studies in the country. In addition, the demand for preventive cardiology therapies is increasing the clinical trial pipeline for cholesterol-lowering drugs and hypertension medications. All these factors contribute to market growth.
Furthermore, the growing investment in drugs for cardiometabolic diseases is boosting the pipeline of cardiovascular clinical trials in the UK, as pharmaceutical companies develop treatments for lipid disorders, heart failure, and inflammation. Besides, large-scale late-phase clinical trials are underway in various parts of the world, involving more than 10,000 participants, which is driving greater demand for UK-based clinical trial sites due to their specialized facilities. Moreover, research into new modes of action, such as inhibiting PCSK9 with RNA-based drugs and anti-inflammatories, is generating interest in early- and mid-phase clinical trials. Also, cooperation between international sponsors and domestic research networks is speeding up site activation and the patient enrollment process. Besides, there is intense competition among companies to demonstrate better cardiovascular outcomes, leading to a higher number of trials involving comparative and combination studies. Furthermore, regulatory pressure for the new drug discovery process is driving a rapid transition from Phase II to Phase III clinical trials.
In addition, government support, both public and private, is helping translational research progress to clinical phase trials. For example, in January 2026, Novo Nordisk announced the extension of its cardiovascular outcome studies in the UK, following increased clinical focus on reducing obesity-related cardiovascular risks. Thus, such an increase in the growing number of investments in the field of cardiology and late-stage pipelines is anticipated to propel the market growth.
In the country, the integrated infrastructure of the National Health Service (NHS) enables access to ~67 million patient records, which is expected to drive the recruitment and real-world evidence generation for cardiovascular clinical trials. In addition, the growing prevalence of cardiovascular disease (~7.6 million patients) has driven an increase in clinical trials, further contributing to market growth.
The UK cardiovascular clinical trials industry is growing due to rising cardiovascular disease burden in the country, regulatory acceleration and adaptive trial frameworks in the UK, and increasing investment in cardiovascular drugs innovation and late-stage pipelines. Due to the rising incidence of cardiovascular disease across the UK, there is continued demand for long-term, large-scale clinical trials. Cardiovascular conditions like heart failure, coronary heart disease (CHD), atrial fibrillation, and ischemic heart disease require ongoing innovations in medications and treatment. This is mainly responsible for the growing number of clinical trials in the country, as these trials are usually conducted using evidence from real-world experiences from NHS databases.
The data published by the British Heart Foundation (BHF) in January 2026 stated that nearly 7 million people currently live with cardiovascular disease in England. The growing and aging population is further expected to boost the rate of CVDs, owing to improved survival rates from cardiovascular events. As the risk of CVD increases with age, by 2030, the population in England aged 65-84 is anticipated to increase by 29% and those aged over 85 by 61%. Furthermore, CVDs are also responsible for ~26% (140,000) of the total deaths in the country per year, which equates to 380 people per day. Amongst which, 38,000 people die under the age of 75 in England each year. Such a growing burden of CVDs in the country has increased the demand for new interventions and treatments, as the government and the public health authorities-led efforts aimed at reducing deaths from cardiovascular disease are providing a steady stream of financial support to clinical studies in the country. In addition, the demand for preventive cardiology therapies is increasing the clinical trial pipeline for cholesterol-lowering drugs and hypertension medications. All these factors contribute to market growth.
Furthermore, the growing investment in drugs for cardiometabolic diseases is boosting the pipeline of cardiovascular clinical trials in the UK, as pharmaceutical companies develop treatments for lipid disorders, heart failure, and inflammation. Besides, large-scale late-phase clinical trials are underway in various parts of the world, involving more than 10,000 participants, which is driving greater demand for UK-based clinical trial sites due to their specialized facilities. Moreover, research into new modes of action, such as inhibiting PCSK9 with RNA-based drugs and anti-inflammatories, is generating interest in early- and mid-phase clinical trials. Also, cooperation between international sponsors and domestic research networks is speeding up site activation and the patient enrollment process. Besides, there is intense competition among companies to demonstrate better cardiovascular outcomes, leading to a higher number of trials involving comparative and combination studies. Furthermore, regulatory pressure for the new drug discovery process is driving a rapid transition from Phase II to Phase III clinical trials.
In addition, government support, both public and private, is helping translational research progress to clinical phase trials. For example, in January 2026, Novo Nordisk announced the extension of its cardiovascular outcome studies in the UK, following increased clinical focus on reducing obesity-related cardiovascular risks. Thus, such an increase in the growing number of investments in the field of cardiology and late-stage pipelines is anticipated to propel the market growth.
UK Cardiovascular Clinical Trials Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the UK cardiovascular clinical trials market report based on phase, study design, and indication:Phase Outlook (Revenue, USD Million, 2021-2033)
- Phase I
- Phase II
- Phase III
- Phase IV
Study Design Outlook (Revenue, USD Million, 2021-2033)
- Interventional
- Observational
- Expanded Access
Indication Outlook (Revenue, USD Million, 2021-2033)
- Valvular Heart Disease
- Peripheral Artery Disease
- Ischemic Heart Disease
- Pulmonary Arterial Hypertension
- Stroke
- Cardiac Arrhythmias
- Heart Failure
- Other Indications
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. UK Cardiovascular Clinical Trials Market Variables, Trends, & Scope
Chapter 4. UK Cardiovascular Clinical Trials Market: Phase Estimates & Trend Analysis
Chapter 5. UK Cardiovascular Clinical Trials Market: Study Design Estimates & Trend Analysis
Chapter 6. UK Cardiovascular Clinical Trials Market: Indication Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- IQVIA Inc.
- ICON plc
- Parexel International (MA) Corporation
- Medpace Holdings, Inc.
- Charles River Laboratories
- MAC Research
- Sofpromed
- Syneos Health
- Worldwide Clinical Trials
- Laboratory Drug Development
- AstraZeneca
- Novartis
- Pfizer
- Bristol Myers Squibb
- Johnson & Johnson
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 507.8 Million |
| Forecasted Market Value ( USD | $ 892.2 Million |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | United Kingdom |
| No. of Companies Mentioned | 15 |
